New Starts of Psychotropic Medications Dropped During COVID-19
June
24
New starts of antidepressants declined by 7.5%, anxiolytics by 5.6%, and antipsychotics by 2.6% compared with forecast levels during the first five months of the COVID-19 pandemic, according to a new study published in Health Affairs. For all medications, declines in new starts were particularly dramatic during the initial stay-at-home order period from March to May 2020. Though there was a significant rebound in new prescription starts after mid-May, the numbers remained below 2019 levels. There were substantial drops in new starts for patients younger than 18, across all medication classes, with a 34.6% decline in antidepressants, 27.3% in anxiolytics and 22.2% in antipsychotics compared with the expected levels.
© 2025 MMIT
Meet Our Reporters
-
Jill Drachenberg Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jill Drachenberg's Profile -
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile
